Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITE DE ROUEN NORMANDIE has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and is situated in 1 distinct art unit. This indicates a highly focused prosecution profile where all active efforts are concentrated on a single matter within the biotechnology sector. Such a concentrated structure allows for a very specific legal strategy without the need to coordinate across different technical classifications or multiple examiner preferences.
GENEVIEVE S ALLEY is the busiest examiner for the company, managing 1 busiest examiner pending office action. Because there is only a pending office action in the portfolio, this examiner handles all of the company's current work. This results in a highly concentrated prosecution environment where the outcome of the company's current efforts rests with this examiner and the 1 distinct art unit. Practitioners should focus their efforts on this matter, as it represents the full extent of the company's current activity. The outcome of this proceeding will define the company's immediate patent position in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IBRAHIM, MEDINA AHMED | 1 | 87.4% | +12.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859233 | PRODUCTION OF THERAPEUTIC ANTIBODIES BY THE MICROALGAE PHAEODACTYLUM TRICORNUTUM | IBRAHIM, MEDINA AHMED | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859233 | PRODUCTION OF THERAPEUTIC ANTIBODIES BY THE MICROALGAE PHAEODACTYLUM TRICORNUTUM | IBRAHIM, MEDINA AHMED | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859233 | PRODUCTION OF THERAPEUTIC ANTIBODIES BY THE MICROALGAE PHAEODACTYLUM TRICORNUTUM | IBRAHIM, MEDINA AHMED | 1662 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial